与先前一代TKIs相比,一线 osimertinib 在先进的EGFR突变性NSCLC中:现实世界的生存分析
Igor Gomez-Randulfe1, Lauren A Scanlon2, Mathew Carter1
1Department of Medical Oncology The Christie NHS Foundation Trust Manchester UK.
Lung cancer (Amsterdam, Netherlands)
|January 17, 2025
概括
第一线 osimertinib 提供类似的整体存活率 (OS) 以往的EGFR氨酸激酶抑制剂 (TKIs) 对于先进的EGFR突变非小细胞肺癌 (NSCLC). 患有不常见EGFR突变的患者的生存结果较差.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 具有表皮生长因子受体 (EGFR) 突变的非小细胞肺癌 (NSCLC) 是一个重大的临床挑战.
- 针对EGFR的氨酸激酶抑制剂 (TKI) 已经彻底改变了治疗方法,但对测序策略和结果的真实数据至关重要.
研究的目的:
- 为了比较先进EGFR突变NSCLC患者的整体存活率 (OS),接受一线 osimertinib治疗与前一代EGFR TKI相比.
- 在患有不常见EGFR突变的患者中评估OS.
- 探索TKI测序对生存结果的影响.
主要方法:
- 在英国克里斯蒂医院 (2014-2023) 治疗高级EGFR突变NSCLC患者的回顾性队列研究.
- 首线 osimertinib 与 afatinib,erlotinib 或 gefitinib 的比较.
- 使用Kaplan-Meier估计和Cox比例危险模型进行生存分析.
主要成果:
- 在第一线 osimertinib 和前一代 TKIs (16.9 vs 16.6 个月; HR=1, p=0.97) 之间,中位 OS 是可比的.
- 患有不常见EGFR突变的患者的生存率明显较差 (HR=1.664,p=0.002).
- 经过另一次TKI后的奥西默蒂尼布导致的生存寿命比奥西默蒂尼布一线治疗后的另一种治疗更短 (HR=2.062,p=0.022).
结论:
- 第一线 osimertinib 在先进的EGFR突变NSCLC中表现出与早期EGFR TKIs相比的可比操作系统.
- 不常见的EGFR突变与低生存率有关.
- 需要进一步的研究,以优化治疗不常见突变和测序策略.
关键词:
欧洲农业基金会 (EGFR) 是一个基金.肺癌是一种肺癌.在NSCLCLC中,我们可以看到.奥西默蒂尼布 (Osimertinib) 是一种药物.RW RW 在线播放这就是为什么RWD是RWD.现实世界的真实世界.这里是TKI TKI.更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.0K
相关概念视频
01:21Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
01:20Comparing the Survival Analysis of Two or More Groups
141
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
141